References

How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 137 CE courses, most popular
$95Add to cart
Pick Your Courses
Up to 8 CE hours
$50Add to cart
Individual course$20Add to cart
The page below is a sample from the LabCE course Liquid Biopsy Assays. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Liquid Biopsy Assays (online CE course)
References

Alix-Panabieres C, Pantel K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov. May 2016;6(5):479-491. Available at: http://cancerdiscovery.aacrjournals.org/content/6/5/479.full. Accessed April 20, 2020.
Balaj L, Laurent LC. exRNA website. First CLIA-validated exosome-based clinical liquid biopsy test is launched. Updated January 27, 2016. Available at: https://exrna.org/first-clia-validated-exosome-based-clinical-liquid-biopsy-test-is-launched/. Accessed April 20, 2020.
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. Feb 19 2014;6(224):224ra224. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017867/. Accessed April 20, 2020.
Bhadra K, Mellert H, Pestano, G. Adoption of Liquid Biopsy Tests for NSCLC. Clinical Lab Products [online magazine]. June 5, 2017. Available at: http://www.clpmag.com/2017/06/adoption-liquid-biopsy-tests-nsclc/. Accessed April 20, 2020.
Biocept website. Biocept's Technology and Circulating Tumor Cells (CTCs). Available at: https://biocept.com/technology/. Accessed April 20, 2020.
Boyle T. Liquid Based Diagnostics. Moffitt Cancer Center website. Available at: https://www.moffitt.org/media/6061/boyle-session_liquid-biopsy-diagnostics.pdf. Accessed April 20, 2020.
Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr Opin Genet Devel. February 2017;42:14-21.
CELLSEARCH® Circulating Tumor Cell Test website. Available at: https://www.cellsearchctc.com/. Accessed April 20, 2020.
CELLSEARCH® Circulating Tumor Cell Test website. Menarini-Silicon Biosystems Completes Acquisition of CELLSEARCH® Assets. BOLOGNA, Italy and Philadelphia, PA. April 3, 2017. Available at: https://www.cellsearchctc.com/menarini-silicon-biosystems-completes-acquisition-cellsearch%C2%AE-assets. Accessed April 20, 2020.
Cleveland Clinic website. Tissue Biopsy. Available at: https://my.clevelandclinic.org/health/diagnostics/15458-biopsy-overview. Accessed April 20, 2020.
Contreras-Naranjo JC, Wu HJ, Ugaz VM. Microfluidics for exosome isolation and analysis-enabling liquid biopsy for personalized medicine. Lab Chip. 2017;17:3558-3577.
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. August 2013;10(8):472-484.
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. September 2008;14(9):985–990. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820391/. Accessed April 20, 2020.
Dressman D, Yan H, Traverso G, KInzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. July 22, 2003;100(15):8817–8822. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC166396/. Accessed April 20, 2020.
Gingras I, Salgado R, Ignatiadis M. Liquid biopsy: will it be the ‘magic tool’ for monitoring response of solid tumors to anticancer therapies? Current Opinion in Oncology. November 2015;27(6):560-567.
Heitzer E, Ulz P, Geigl JB. Circulating Tumor DNA as a Liquid Biopsy for Cancer. Clin Chem. December 2014;61(1):112–123. Available at: http://clinchem.aaccjnls.org/content/61/1/112. Accessed April 20, 2020.
Insight Pharma Reports website. Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management. Available at: http://www.insightpharmareports.com/uploadedFiles/Reports/Reports/Liquid_Biopsy_Report/Liquid-Biopsy-Brochure.pdf. Accessed April 20, 2020.
Karachaliou N, Mayo-de-las-Casas C, Molina-Vila MA, Rossel R. Real-time liquid biopsies become a reality in cancer treatment. Ann Translation Med. March 2015;3(3):36. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356857/. Accessed April 20, 2020.
Kinde I, Wu J, Papadopoulos N, Kinzler KW, Vogelstein B. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A. June 7, 2011;108(23): 9530–9535. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111315/. Accessed April 20, 2020.
Krilov L, ASCO Staff. Trending in Cancer Research: Liquid Biopsy Tests, Part II: ctDNA in Action - Emerging Uses. July 17, 2017. Available at: https://www.asco.org/about-asco/press-center/cancer-perspectives/trending-cancer-research-liquid-biopsy-tests. Accessed April 20, 2020.
Krishnamurthy N, Spencer E, Torkamani A, Nicholson L. Liquid Biopsies for Cancer: Coming to a Patient near You. J Clin Med. January 4, 2017;6(1):3. Available at: http://www.mdpi.com/2077-0383/6/1/3/htm#sec4-jcm-06-00003. Accessed April 20, 2020.
Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Inter J Cancer. June 19, 2002;100(5): 542–548. Available at: http://onlinelibrary.wiley.com/doi/10.1002/ijc.10526/full. Accessed April 20, 2020.
Liquid-biopsy.gene-quantification.info website. Available at: http://liquid-biopsy.gene-quantification.info/. Accessed April 20, 2020.
Mao C, Yuan JQ, Yang ZY, Fu XH, Wu XY, et al. Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis. Medicine. May 2015;94(21):e775. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616411/. Accessed April 20, 2020.
Norton SE, Lechner JM, Williams T, Fernando MR. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem. October 2013;46(15):1561–1565. Available at: https://www.sciencedirect.com/science/article/pii/S0009912013002798?via%3Dihub. Accessed April 20, 2020.
Novella Clinical website. The Promise of Liquid Biopsy Technology [whitepaper]. Available at: http://novellaclinical.com/content/uploads/2016/09/Novella_Oncology_Liquid-Biopsy_Whitepaper.pdf. Accessed April 20, 2020.
Pailler E, Adam J, Barthelemy A, Oulhen M, Auger N, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. Jun 20, 2013;31(18):2273-2281. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23669222. Accessed April 20, 2020.
Perakis S, Speicher MR. Emerging concepts in liquid biopsies. BMC Medicine. 2017;15:75. Available at: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0840-6. Accessed April 20, 2020.
Perez-Callejo D, Romero A, Provencio M, Torrente M. LIquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res. 2016;5(5):455-465. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099509/. Accessed April 20, 2020.
Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PloS One. 2012;7(11): e47020. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492590/. Accessed April 20, 2020.
Qin Z, Ljubimov VA, Zhou C, Tong Y, Liang J. Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016;35:36. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823888/. Accessed April 20, 2020.
Qiu M, Wang J, Xu Y, Ding X, Li M, et al. Circulating Tumor DNA is Effective for the Detection of EGFR Mutation in Non-Small Cell Lung Cancer: A Meta-analysis. Cancer Epidemiol Biomarkers Prev. Jan 2015;24(1):206-212. Available at: http://cebp.aacrjournals.org/content/24/1/206.long. Accessed April 20, 2020.
Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J. June 1, 2016;14:211–222. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913179/. Accessed April 20, 2020.
Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell lung cancer. Biologics. 2013;7:91–101. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643289/. Accessed April 20, 2020.
Roche Molecular Diagnostics website. cobas® EGFR Mutation Test v2. Available at: https://molecular.roche.com/assays/cobas-egfr-mutation-test-v2-ce-ivd/. Accessed April 20, 2020.
Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer. July 2010;46(10):1773-1780. Available at: http://www.ejcancer.com/article/S0959-8049(10)00305-9/fulltext. Accessed April 20, 2020.
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. November 1, 2014;32(31):3483-3489. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209100/. Accessed April 20, 2020.
Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. September 2006;24(26):4270–4276.
Vallée A, Marcq M, Bizieux A, Kouri C, Lacroix H, et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Lung Cancer. November 2013;82(2):373–374.
van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharm Rev. July 2012;64(3):676–705. Available at: http://pharmrev.aspetjournals.org/content/64/3/676. Accessed April 20, 2020.
Walker N. American Pharmaceutical Review website. The New Wave in Cancer Screening: Liquid Biopsy Testing. April 30, 2017. Available at: http://www.americanpharmaceuticalreview.com/Featured-Articles/337584-The-New-Wave-in-Cancer-Screening-Liquid-Biopsy-Testing/. Accessed April 20, 2020.
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nature Reviews Cancer. February 24, 2017;7:223-238.